The precise ST regimen is selected based on the tumor subtypes, defined by hormone receptor (HR) and HER2 status, as well as by other biomarkers, such as PD-L1 and germline BRCA1/2 gene mutations [1, 2]. The gene discussed is ERBB2; the disease is neoplasm.